Janux Therapeutics Financial Ratios
NASDAQ: JANXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
18.39-0.11 (-0.59%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Janux Therapeutics ratio analysis
Janux Therapeutics earned a net margin of -1136.3% in FY 2025, down from -651.6% a year earlier. Return on equity reached -11.9%, meaning Janux Therapeutics generated -0.12 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Janux Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Price / sales | 84.58 | 273.73 | 58.43 | 63.42 | 127.65 | — |
| Price / book | 0.88 | 2.83 | 1.37 | 1.70 | 1.27 | — |
| Operating margin | -1,576.7% | -933.6% | -902.9% | -779.0% | -905.4% | — |
| Net margin | -1,136.3% | -651.6% | -721.2% | -732.2% | -898.3% | — |
| Free cash flow margin | -832.8% | -417.2% | -648.6% | -573.2% | -507.5% | — |
| Return on equity (ROE) | -11.9% | -6.7% | -16.9% | -19.7% | -8.9% | — |
| Return on assets (ROA) | -11.3% | -6.5% | -15.3% | -17.3% | -8.6% | -41.8% |
| Current ratio | 39.04 | 59.21 | 26.80 | 20.14 | 29.46 | 5.05 |
| Revenue growth | -5.6% | 31.0% | -6.1% | 136.8% | — | — |